Vegar Johansen Dagenborg
Overview
Explore the profile of Vegar Johansen Dagenborg including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
323
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Wiig J, Dagenborg V, Larsen S
Colorectal Dis
. 2024 Dec;
PMID: 39635974
Aim: The aim of this work is to report actual overall survival (AOS) at 5 and 10 years after multimodal treatment for locally recurrent rectal or sigmoid cancer (LRRC) and...
2.
Dagenborg V, Brudvik K, Lund-Andersen C, Torgunrud A, Lund-Iversen M, Flatmark K, et al.
Ann Surg
. 2024 Aug;
280(5):745-752.
PMID: 39185557
Objective: To study outcomes after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (CRS-HIPEC) in patients also treated for colorectal liver metastases (CLM). Background: Colorectal cancer (CRC) frequently metastasizes to the liver...
3.
Nygaard V, Ree A, Dagenborg V, Borresen-Dale A, Edwin B, Fretland A, et al.
Cancer Res Commun
. 2023 Mar;
3(2):235-244.
PMID: 36968142
Significance: CLM is an important cause of colorectal cancer mortality where the majority of patients have yet to benefit from immunotherapies. In this study of gene expression profiling analyses, we...
4.
Dagenborg V, Marshall S, Grzyb K, Fretland A, Lund-Iversen M, Maelandsmo G, et al.
Front Oncol
. 2021 Jun;
11:671629.
PMID: 34178659
Background: The subtype, density and location of tumor infiltrating T-cells are being explored as prognostic and predictive biomarkers in primary colorectal cancer (pCRC) and colorectal liver metastases (CLM). Very limited...
5.
Aghayan D, Kazaryan A, Dagenborg V, Rosok B, Fagerland M, Bjornelv G, et al.
Ann Intern Med
. 2020 Nov;
174(2):175-182.
PMID: 33197213
Background: Despite the recent worldwide dissemination of laparoscopic liver surgery, no high-level evidence supports the oncologic safety of this approach. Objective: To evaluate long-term oncologic outcomes after laparoscopic versus open...
6.
Dagenborg V, Marshall S, Yaqub S, Grzyb K, Boye K, Lund-Iversen M, et al.
Cancer Biol Ther
. 2020 Feb;
21(5):432-440.
PMID: 32098573
Patients with colorectal liver metastases (CLM) commonly receive neoadjuvant chemotherapy (NACT) prior to surgical resection. NACT may induce immunogenic cell death with subsequent recruitment of T-cells to the tumor microenvironment,...
7.
Hausken J, Fretland A, Edwin B, Andersen M, Dagenborg V, Bjornelv G, et al.
Ann Surg
. 2019 Jan;
270(2):193-199.
PMID: 30676382
Objective: We conducted a randomized, controlled, noninferiority trial to investigate if intravenous, multimodal, patient-controlled analgesia (IV-PCA) could be noninferior to multimodal thoracic epidural analgesia (TEA) in patients undergoing open liver...
8.
Ostrup O, Dagenborg V, Rodland E, Skarpeteig V, Silwal-Pandit L, Grzyb K, et al.
Oncotarget
. 2017 Nov;
8(44):76290-76304.
PMID: 29100312
Background: Metastatic colorectal cancer (CRC) is associated with highly variable clinical outcome and response to therapy. The recently identified consensus molecular subtypes (CMS1-4) have prognostic and therapeutic implications in primary...
9.
Fretland A, Dagenborg V, Bjornelv G, Kazaryan A, Kristiansen R, Fagerland M, et al.
Ann Surg
. 2017 Jun;
267(2):199-207.
PMID: 28657937
Objective: To perform the first randomized controlled trial to compare laparoscopic and open liver resection. Summary Background Data: Laparoscopic liver resection is increasingly used for the surgical treatment of liver...